Karnataka | 15 January 2025 | News
JNCASR develops new system for wearable devices that can detect stress
Using silver wire network on a stretchable material, scientists fro...Read more
Telangana | 31 December 2024 | Interviews
What key initiatives and strategic changes is the Telangana government implementing to attract investments in ...Read more
MedTech | 17 January 2025 | News
Medtech manufacturers hail CDSCO move on stopping import of used medical devices
Medical device manufacturers have hailed the clarification by the Central Drugs Standard Control Organization ...Read more
Medical Diagnostic | 22 January 2025 | News
AIIMS Jammu and 4baseCare sign MoU to launch Centre for Advanced Genomics and Precision Medicine
AIIMS Jammu and Bengaluru-based startup 4baseCare have signed a Memorandum of ...Read more
Supplier | 21 January 2025 | News
Sartorius opens new bioprocessing automation lab in Ontario
The life science group Sartorius and Canada's McMaster Universi...Read more
People | 09 January 2025 | News
Medanta appoints leading urologist Dr Sanjay Gogoi as Chairman of Renal Care Institute
Reinforcing its leadership in advanced kidney care and transplantation, Medanta has appointed globally renowne...Read more
Academics | 20 January 2025 | News
IIHMR Bangalore and RED Health Academy launch first-of-its-kind PG certificate course
International Institute of Health Management Research (IIHMR...Read more
Text blogs | 31 December 2024 | Views
Key Skills & Salary Trends in Healthcare & Pharma for 2025
Evolving Skillsets The healthcare and pharmaceutical industries are undergoing profound transformations, led ...Read more
Indian Pharma Hits R&D Salvo
Pharma companies are constantly on the quest to discover the next big game-changer drug or therapeutic by leveraging the latest, cutting-edge innovation. While it is notable that biopharma companies eased up on their research and development (R&D) spending in FY 2022-23 after the world was hit by COVID-19- induced economic slowdown, the budget for R&D has witnessed a steady increase. Departing a bit from their traditional drug portfolios, companies are increasingly focusing on R&D in nextgeneration therapies to drive innovation, particularly in complex generics, biosimilars, cell and gene therapies and novel drug delivery systems.
For Feedback, please email us at: communications@mmactiv.com